CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Henan Livu Pharmaceutical Co Ltd is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Henan Livu Pharmaceutical Co Ltd
Phone: +86 37165797244p:+86 37165797244 Zhengzhou, HEN  450008  China Fax: +86 37165797245f:+86 37165797245

Business Summary
Henan Livu Pharmaceutical Co Ltd is a China-based company principally engaged in the research and development, production, sales and technical consulting services of biochemical drugs and modern Chinese medicines. The Company’s products include tablets, granules, hard capsules, powders, mixtures, oral liquids, wines and solutions and other medicines, covering the medical fields of cardiovascular, cerebrovascular, tumor, gynecology, orthopedics, etc.
(Source: Company's Website)

Scores and Ratings
FRISK®
Score
Z''
Score
PAYCE®
Score
DBT
Index
Moody's
Rating
Fitch
Rating
DBRS
Rating
-------

Financials, News and Filings
Latest
Statement
Last
Audit

News
SEC
Filings
Bankruptcy
Filings
Suit &
Judgment
Filings
Tax
Lien
Filings
9/30/201412/31/2013-----

General Information
Outstanding Shares: 27,000,000 (As of 9/30/2014)
Fax Number: +86 37165797245


Copyright © 2023 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Friday, July 21, 2023